NASDAQ · Biotechnology

Exelixis, Inc. (EXEL) Stock

$59.02 +0.99% NASDAQ: EXEL Healthcare

Valuation

MetricValue
Price$59.02
Market Cap$14.83B
P/E Ratio17.78
P/B Ratio7.96
P/S Ratio6.04
EPS (TTM)$2.78
52-Week High$61.14
52-Week Low$33.76
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE42.49%
ROA34.50%
ROCE45.56%
Gross Margin96.44%
Operating Margin39.43%
Net Margin35.33%
Debt/Equity0.09
Current Ratio3.55

Annual Financials (USD)

Metric20212022202320242025
Revenue$1.4B$1.6B$1.8B$2.2B$2.3B
Operating Profit$287.0M$201.0M$171.0M$605.0M$872.0M
Net Profit$231.0M$182.0M$208.0M$521.0M$783.0M
EPS$0.72$0.56$0.65$1.76$2.78
Op Margin20.0%12.5%9.3%27.9%37.6%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$2.6B$3.1B$2.9B$2.9B$2.8B
Total Liabilities$406.0M$583.0M$678.0M$703.0M$683.0M
Cash$647.0M$501.0M$263.0M$217.0M$482.0M
Borrowings$51.0M$190.0M$190.0M$191.0M$173.0M

Latest News

EXEL: Lowering target price to $61.00 Argus Research · Jul 15, 2026 Is Exelixis (EXEL) Expensive After Its Recent Rally Or Still Undervalued? Simply Wall St. · Jul 11, 2026 Exelixis (EXEL) Stock Trades At A Discount After Its 236% Run Simply Wall St. · Jul 11, 2026 3 Under-the-Radar Stocks to Buy and Hold Motley Fool · Jul 10, 2026 EXEL Stock Soars 26.8% in Three Months: Is There More Room for Growth? Zacks · Jul 9, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$401.0M$363.0M$333.0M$700.0M$884.0M
Investing Cash Flow$-107.0M$-663.0M$-190.0M$-183.0M$311.0M
Financing Cash Flow$-15.0M$-23.0M$-579.0M$-691.0M$-1.0B
Net Cash Flow$343.0M$-161.0M$-240.0M$-46.0M$265.0M
Free Cash Flow$337.0M$224.0M$170.0M$634.0M$844.0M

Valuation & Return Ratios

MetricValue
PEG Ratio0.33
EV / EBITDA14.03
FCF Yield7.88%
Quick Ratio3.38
Interest Coverage0.00
Return 1Y45.58%
Return 3Y162.13%
Return 5Y170.15%

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
ALPMYAstellas Pharma Inc. $13.13 -0.68% 13.19 $23.52B 3.12%
AZNAstraZeneca PLC $158.78 -0.84% 24.77 $246.25B 1.27%
CRISCuris, Inc. $0.71 -3.69% -0.06 $1.38M 0.00%
GMABGenmab A/S $29.00 -2.62% 21.45 $17.80B 0.00%
HCMHUTCHMED (China) Limited $11.25 +0.99% 4.28 $1.96B 0.00%

About Exelixis, Inc.

Exelixis, Inc. is led by CEO Michael Morrissey, employs 1,077 people, headquartered in Alameda, US, publicly traded since 2000.

Exelixis, Inc. (EXEL) stock trades at $59.02 with a market capitalization of $14.83B. The stock is valued at a price-to-earnings (P/E) ratio of 17.78, price-to-book of 7.96, price-to-sales of 6.04. Over the past 52 weeks the stock has ranged between $33.76 and $61.14, and currently trades 3.5% below its 52-week high.

On profitability, Exelixis, Inc. generates a return on equity (ROE) of 42.49% — well above the market average, a sign of a high-quality business, return on capital employed of 45.56%, an operating margin of 39.43%, a net profit margin of 35.33%.

Related Healthcare Stocks

LLY Eli Lilly and Company $1169.93 -1.58% JNJ Johnson & Johnson $256.48 -0.76% ABBV AbbVie Inc. $272.42 +0.39% MRK Merck & Company, Inc. Common Stock (new) $142.40 -0.28% UNH UnitedHealth Group Incorporated Common Stock (DE) $370.95 -1.34% NVS Novartis AG $143.11 -0.12% AZN AstraZeneca PLC $158.78 -0.84% TMO Thermo Fisher Scientific Inc $651.98 -1.52% AMGN Amgen Inc. $407.44 -1.37% GILD Gilead Sciences, Inc. $147.10 +0.17% ABT Abbott Laboratories $98.49 -0.24% NVO Novo Nordisk A/S $38.18 -0.21%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides